The Coronary Artery Surgery Study (CASS) (Circulation 1990;82:1629-1646 T he Coronary Artery Surgery Study (CASS) sponsored by The National Heart, Lung, and Blood Institute is designed to assess the effect of coronary bypass surgery on mortality and
The Coronary Artery Surgery Study (CASS) randomized 780 patients to an initial strategy of coronary surgery or medical therapy. Of medically randomized patients, 6% had surgery within 6 months and a total of 40%o had surgery by 10 years. At 10 years, there was no difference in cumulative survival (medical, 79%, vs. surgical, 82%; NS) and no difference in percentage free of death and nonfatal myocardial infarction (medical, 69%o vs. surgical, 66%; NS). Patients with an ejection fraction of less than 0.50 exhibited a better survival with initial surgery treatment (medical, 61% vs. surgical, 79%; p =0.01). Conversely, patients with an ejection fraction greater than or equal to 0.50 exhibited a higher proportion free of death and myocardial infarction with initial medical therapy (medical, 75% vs. surgical, 68%; p=0.04) although long-term survival remained unaffected (medical, 84% vs. surgical, 83%; p=0.75). There were no significant differences either in survival and freedom from nonfatal myocardial infarction, whether stratified on presence of heart failure, age, hypertension, or number of vessels diseased. Thus, 10-year follow-up results confirm earlier reports from CASS that patients with left ventricular dysfunction exhibit long-term benefit from an initial strategy of surgical treatment. Patients with mild stable angina and normal left ventricular function randomized to initial medical treatment (with an option for later surgery if symptoms progress) have survival equivalent to those patients randomized to initial surgery. (Circulation 1990; 82:1629 -1646 selected nonfatal end points. The study includes 780 patients randomized between August 1975 and May 1979 . Results for 5-year survival and incidence of myocardial infarction have been publishedl"2 and showed no significant differences for all patients, for subgroups stratified by clinical presentation at the time of randomization, or by angiographic criteria defined by extent of coronary disease or severity of left ventricular dysfunction. Seven-year follow-up of these same patients revealed a survival benefit for those patients randomized to surgical treatment who had an ejection fraction of less than 0.50, particularly those with triple-vessel coronary disease.3 All other patient subsets, however, continued to show no survival benefit from bypass surgery.
See p 1859 Eleven-and 12-year results from two other major multicenter randomized trials of patients with stable ischemic coronary disease have recently been reported.45 Both studies show benefit of surgery in the high-risk angiographic subsets. The Veterans Adminby guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from istration Cooperative Study Group4 reported attenuation of this survival benefit in surgically assigned patients beyond their fifth year of study participation. Similar attenuation of earlier benefit was also observed in the European Coronary Surgery Study. 5 The CASS randomized trial had a later starting date than did either the Veterans Administration or European studies, enrolled patients with angina of lesser severity, and included a cohort of asymptomatic patients after myocardial infarction. This report presents complete patient follow-up results at 10 years after randomization. Methods Details of the CASS protocol, randomization procedures, quality control measures, and major baseline characteristics have previously been published.6 CASS was designed as a randomized clinical trial to assess the results of an initial strategy of surgery combined with continued medical therapy versus medical therapy. CASS involved 15 clinical sites, of which 11 participated both in the registry and in the randomized trial, and four were registry sites only. Of the 24,959 patients enrolled in the registry between July 1974 and May 1979, 16,626 were enrolled at the 11 randomizing sites between August 1975 and May 1979 and were therefore candidates for participation in the trial. After baseline coronary arteriography for suspected or proven coronary disease at these 11 sites, 2,099 patients were considered eligible, of whom 780 entered the randomized trial.
At each of the participating sites, cardiac catheterization logs were maintained in order that all patients having arteriography at these sites would be included in the CASS registry. Ninety-four percent of patients having arteriography at the participating sites consented to their inclusion in the registry and accompanying limited clinical follow-up. Twenty-eight percent of patients were excluded from consideration for randomization because of normal coronary vessels or insignificant disease, most of whom had minimal, if any, ischemic pain symptoms. Patients who had prior coronary bypass graft surgery, exceeded 65 years of age, or could not be included because of geographic or language barriers, were excluded as were those with an ejection fraction of less than 0.35 and those with overt heart failure or shock as the predominant symptoms. Patients with left main lesions exceeding or equal to 70% were excluded; however, 14 patients with left main lesions between 49% and 69% lumen reduction were included. Patients with angina severity of Canadian Cardiovascular Society (CCS) class 3 or 4 were excluded from randomization.7 Baseline information included clinical, laboratory, and angiographic assessments that are detailed in prior publications from CASS investigators. 2, 6 Coronary arteriograms and left ventriculograms were obtained and analyzed by angiographers at the clinical sites by using preformatted coding forms that divided the coronary vasculature into 27 discrete segments. Coronary lesion severity was estimated based on visual estimate of percent diameter reduction. The number of diseased vessels was based on a 70% threshold of diameter reduction with the exception of the left main coronary artery for which a 50% threshold was used. Requirement for participation in the trial included presence of operable coronary vessels containing lesion or lesions of 70% or greater diameter lumen narrowing for any vessel segment.
A total of 2,099 (12.6%) registry patients met entry criteria and were eligible for randomization, of whom 780 consented to be randomized to immediate surgery or to medical treatment. The remaining 1,319 patients did not participate because of physician or patient refusal, and they constituted a subgroup of "randomizable" but nonrandomized patients whose follow-up is reported separately.8 Patients were randomized within three prerandomization groups. Group A included patients with angina and an ejection fraction greater than or equal to 0.50; group B included those patients with angina and an ejection fraction of less than 0.50 (86% of patients in this group had an ejection fraction of between 0.35 and 0.50); group C included asymptomatic patients who were within 6 months of a well-documented myocardial infarction. Randomization for groups A and B was further stratified by number of vessels diseased and by clinical center; group C was further stratified by ejection fraction and number of vessels diseased. There were no significant differences between the medical and surgical groups for any of the clinical variables documented at enrollment.
As of September 2, 1988 , vital status was known for 778 randomized patients; two surgically assigned patients were lost to follow-up after 4.5 and 10.5 years. Diagnosis of myocardial infarction was based on data collected in three different ways. Episodes of infarction were identified by annual telephone follow-up interview with the patient by using a structured questionnaire. If a patient died, mortality data were assessed for infarct detection by a physician or data coordinator by using information from hospital records or death records. Additionally, for each hospitalization of 5 or more days' duration, physicians at each clinical site reviewed hospital records for the presence of localized depolarization abnormalities with abnormal Q waves on the electrocardiogram or changes in serum levels of myocardial enzymes along with a consistent clinical history as criteria for the diagnosis of definite or probable infarction. Collection of hospital discharge summaries from which this latter information was obtained was discontinued after all patients had reached a minimum of 3.6 years of follow-up (mean follow-up, 5.5 years).
Significant differences (p<0.05 by two-tailed tests) in survival and infarction between the medical and surgical groups were tested by the log-rank test.9 Life-table estimates were calculated to 10 years. The standard error was estimated by the Greenwood method.10 The probability values cited in each figure are uncorrected for multiple comparisons. All study by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from A summary of survival and freedom from both death and infarction in CASS patients is given in Tables 1 and   390 383 375 YEAR by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from FIGURE 2. Life-table plots of patients with an ejection fraction greater than or equal to 0.50 and stable angina * show similar 10-year survival (top panel); however, the percentage ofpatients free of death and infarction (bottom panel) is statistically higher in medically treated groups (p=0.024). The event-free graph in surgically treated patients shows an initial decline resulting from perioperative infarctions, a plateau phase for approximately 3 years, and a slightly accelerating increase in event frequency beyond 6 years. These patients* were categorized at the time of randomization as group A.
2. For CASS patients as a whole, there was no significant difference in medical versus surgical 10-year survival (medical, 79% vs. surgical, 82%;p=0.25). Figure 1 shows both cumulative survival and freedom from both death and nonfatal infarction (p=0.41).
Normal Left Ventricular Function
Group A patients, who had a normal ejection fraction and mild stable angina, had longer eventfree survival (medical, 76% vs. surgery, 66%; p=0.024) with medical treatment than with surgery ( Figure 2 ). This observation was corroborated by examining all patients with normal ejection fraction irrespective of symptoms ( Figure 3 ) and is evident for those patients with three-vessel disease ( Figure 4 ).
The event rates in medically versus surgically randomized patients in Figure 2 (groups with normal left ventricular [LV] ejection fraction) show an initial divergence resulting from perioperative infarction. This is followed by a 3-year plateau in surgically randomized patients when events increase in medically randomized patients at a relatively constant rate. By 6 years after randomization, there is progressive divergence of cumulative survival and infarct-free survival in medically versus surgically randomized patients.
Abnormal Left Ventricular Function
Group B patients, who had an ejection fraction of between 0.35 and 0.5 with stable mild angina, exhibited an 80% 10-year survival in those assigned to surgery, which substantially exceeded the 59% survival for medically randomized patients (p=0.01) ( Figure 5 ). This observation was confirmed in the 160 randomized patients who had an LV ejection fraction of less than 0.50. The 10-year 79% survival of these patients with LV dysfunction who were randomized to surgery exceeded the 61% survival for medically randomized patients (p=0.01) ( Figure 6 ). This difference in survival was also evident in the subset of patients who had both an ejection fraction of less than 0.50 and concomitant three-vessel coronary disease ( Figure 7 
Angina Severity
Analysis of cumulative survival in patients stratified on the basis of angina severity (Table 2) showed no significant differences between medical and surgical treatment. Event-free survival in patients with CCS class I angina was better for those patients randomized to medical therapy than to surgery compared with patients with class 2 angina. Age and hypertensive history were analyzed (Table 1) because of their association with coronary disease mortality; however, neither was predictive of superior outcome with either treatment.
Extent of Coronary Disease
No significant survival or event rate benefits were observed for patients with one-, two-, or three-vessel disease (Table 2 ; Figures 8, 9 , and 10). The overall 10-year survival for all randomized patients with one-vessel disease was 83%, for two-vessel disease was 81%, and for three-vessel disease was 75%.
The European Cooperative Study observed improved survival with surgical therapy in patients with LAD stenosis.12 That study used a 50% threshold to define diseased vessels. In CASS, however, no significant survival or event rate advantage for initial surgery was observed in patients with LAD obstruction, irrespective of whether a 50% or 70% diameter reduction threshold was used, or whether the lesion was proximal or midvessel in location, or whether present in conjunction with one-, two-, or threevessel disease. Incremental Therapy During 10 years of follow-up, surgical treatment occurred in 40% of medically randomized patients. Figures 5, 6 , and 7 all show a progressively increasing benefit of surgical treatment from year 3 through year 10 in CASS patients with LV dysfunction. The trend toward surgical benefit previously reported at 5 years became more evident at 7 years,3 and is even more prominent in the present report. In contrast, the VA study survival curves reach a maximal difference between medically and surgically assigned patients at 7 years (p=0.05); however, by year 11, the survival difference is no longer significant. The attenuation of the early surgical benefit in the VA patients may reflect a variety of factors including a more adverse risk factor profile at the time of study entry, a somewhat lower initial graft patency rate (VA, 69% patency at 15 months in an 84% sample of patients vs. CASS, 82% patency at 18 months in a 16% sample of patients), increasing rate of graft occlusion over time, and absence of internal mammary usage as a conduit to the LAD artery at the time of VA study recruitment.13 Also, there may have been a difference, during the years after study entry, in aggressive management of risk factors for coronary disease progression such as cigarette usage, blood lipids, and physical activity.
CASS survival results at 5, 7, and 10 years do not demonstrate any selective benefit for medical or surgical treatment selected on the basis of one-, two-, or three-vessel involvement as a measure of extent of coronary disease, whether a 50% or 70% threshold for lesion severity is used. This lack of benefit has been a consistent difference in CASS from the results of the European Cooperative Trial (Table 4) . Comparison of the results of the three major randomized clinical trials, however, must consider important differences in patient features, which are highlighted in what better than in the other two trials. CASS medically treated patients also had consistently better survival rates than "equivalent" patients in both the VA study and The European Cooperative Study (Table 4 ).
In the European Cooperative Study, multivariate statistical test of interaction of potential prognostic factors with treatments revealed that proximal LAD stenosis exhibited the greatest predictive statistical power (p<0.07).5 The reports of the European Cooperative Study attributed much of their longterm beneficial effect of surgery to revascularization of proximal LAD lesions.5,12 Similar statistical analysis of CASS randomized patients fails to show that proximal LAD stenosis has any overall predictive effect. There was a trend toward a greater concentration of patients with proximal LAD lesions in the randomizable compared with randomized patients. This bias decreases the number of patients in this subgroup, diminishing statistical power and thus, potentially explaining the difference from the European Cooperative Surgery Study results. Analysis of CASS-eligible and randomized patients does suggest benefit of surgery for patients with LAD lesions and an ejection fraction of less than 0.50.14 A striking feature in CASS is the relatively low 10-year mortality of patients who had a normal ejection fraction, irrespective of the number of diseased coronary vessels. For these patients, long-term survival and, especially, event-free survival was best for patients randomized to an initial strategy of medical therapy. For these cohorts, early bypass surgery was consistently associated with a greater frequency of events beyond 4-5 years. The late increase in coronary events in patients randomized to surgery compared with the medical group corresponds to the deterioration of outcome late after surgery in both the VA 11-year follow-up4 and European Cooperative Study 12-year follow-up reports.5 Both studies show a decline between 5 and 10 years in the statistical significance of differences between surgical and medical randomization.
One possible explanation for the more pronounced decrease in surgical survival after [4] [5] (Tables 1 and 2) are not substantially different from that observed in the VA and European studies ( Table 5 ). The rate of surgery in medically randomized patients varied considerably depending on the clinical or angiographic characteristics. The reasons for surgical treatment in medically randomized patients were documented not only on relevant data forms but also by letter from the principal investigator, detailing the clinical circumstances. For medically randomized patients who had surgery within the first six months after randomization (i.e., 6% "early crossover"), 31% of decisions resulted from worsening symptoms in combination with repeat arteriography and 69% of decisions for surgery were based on patient or physician preference, or both, without a substantial change in symptoms.
Occurrence of late surgery as incremental therapy in medically randomized patients after 6 months reflected physician management decisions in 94% of the patients because of progression of symptoms or progression of angiographic disease. Of the medically assigned patients who received surgery more than 6 months after baseline angiography, 9.2% had a myocardial infarction and 74.2% had repeat coronary arteriography within 6 months preceding surgery. The fact that patients with high and low ejection fractions in the medical group had similar crossover to surgery reduces the chances of bias (Figure 11) . Conversely, the substantial differential in the number of late surgeries in medically randomized patients defined on the basis of one-, two-, or three-vessel disease may obscure long-term differences ( Figure  12) .
The primary analysis of these data was by intent to treat in which patients were analyzed in their assigned treatment group regardless of treatment received. This method is unbiased and is scientifically the most valid method.20,21 Two other analysis methods were introduced in an attempt to deal with the effect of medically assigned patients who later had surgery. The results and conclusions from these censored analyses are detailed in the "Appendix" and did not differ from the primary analyses. An additional concern in the analysis of randomized trials is the use of multiple patient subsets. CASS In an attempt to analyze the effect of medical patients later having surgery, the data were also analyzed by treatment received by using two methods. In the first method, medically assigned patients who later had surgery were censored at the time of surgery. In the second method, medically assigned patients were counted in the medical group until they had surgery, and thereafter they were counted in the surgical group. In both methods, surgically assigned patients who did not have surgery were excluded. Surgical survival was dated from the time of surgery, and medical survival was dated from the average time to surgery at the enrolling hospital in the first year of CASS enrollment. This adjustment in starting time was made to account for the bias that is introduced when noncomparable start times are used and all early deaths are attributed to medicine.
In the intent-to-treat analysis, survival rates were significantly higher for surgically assigned patients who had an ejection fraction of less than 0.50 (Figures 5, 6, and 7 ). Appendix Table 1 shows the 10-year survival rates as estimated by the intent-to-treat analysis and by the two censored analyses. In the by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from In the intent-to-treat analyses, event free rates were significantly higher for medically assigned patients who had an ejection fraction greater than or equal to 0.50 (Figures 2, 3, and 4 ). Appendix Table 2 shows the 10-year event-free rates as estimated by the three analysis methods. In the censored analyses, event-free rates in the medically treated patients decreased by two to four percent points. In the surgically treated patients, event-free rates increased by, at most, one percent point in the first censored analysis and by three to five points in the second censored analysis. Although the differences between medicine and surgery decreased somewhat for each of the analysis methods, the event-free rate is higher in the medically treated patients in each of the subgroups. As in the analyses of mortality, the censored analyses show the same direction of effect as was shown in the intent-toby guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from treat analyses, although the probability values have increased. As was previously the case, the increase in probability values is partly due to decrease in the difference and partly due to decreased power in the censored analyses.
The intent-to-treat analysis is unbiased and is scientifically the most valid method.20,21 The first censored method can introduce bias by removing early deaths and by removing a nonrandom subgroup from the medical group. The second censored method can introduce bias by adding to the surgical group medically assigned patients who have surgery. Because these patients are a subset of the medically assigned group, they do not have the same group characteristics as the patients assigned to surgery. The bias introduced can be in either direction. In patients with an ejection fraction greater than 0.50, the 10-year event-free rate (68%) was significantly lower in the surgically assigned patients who had surgery than the postsurgical event rate (80%) in the medically assigned patients who had surgery (p=0.02). In this case, the medical patients are a low-risk group and the censored analysis improves the overall event-free rate for surgery. On the other hand, in patients with an ejection fraction of less than 0.50 and three-vessel disease, the 10-year survival rate (76%) in the surgically assigned patients was higher than the rate (44%) in medically-assigned patients who had surgery (p=0.09). In this case, the medical patients are a high-risk group and the censored analysis decreases the overall surgical survival. Clearly, adding a subgroup of medically assigned patients to the surgical group changes the characteristics of the surgical group and removes the benefits of randomization. The results from the censored analyses should be regarded cautiously, although as noted, the results and conclusions are not notably different from the primary analyses. 
